E7820 is primarily investigated for its potential therapeutic applications in the treatment of cancer. It functions as an inhibitor of integrin α2 expression, which plays a critical role in angiogenesis, the process by which new blood vessels form. By targeting this mechanism, E7820 aims to disrupt the blood supply to tumors, thereby inhibiting their growth and metastasis. This makes it a promising candidate for use in combination with other anticancer therapies to enhance their efficacy. Additionally, research is ongoing to explore its potential in treating other conditions where angiogenesis is a contributing factor, such as certain inflammatory diseases. Its application in clinical trials continues to provide insights into its safety, tolerability, and effectiveness in various therapeutic contexts.